Questionnaire and Laboratory Data on Vitiligo Vulgaris

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Beth Israel Medical Center
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier:
NCT01206374
First received: September 20, 2010
Last updated: May 13, 2014
Last verified: May 2014
  Purpose

Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.


Condition
Vitiligo Vulgaris

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris

Resource links provided by NLM:


Further study details as provided by St. Luke's-Roosevelt Hospital Center:

Primary Outcome Measures:
  • Quality of life disturbances in people with vitiligo [ Time Frame: point prevalence ] [ Designated as safety issue: No ]
    dermatology life quality indices were you used and correlated with location of disease


Secondary Outcome Measures:
  • self-reporting of vitiligo disease symptoms and history [ Time Frame: single survey ] [ Designated as safety issue: No ]
    Correlation of the patient survey response with chart documentation was performed.


Estimated Enrollment: 300
Study Start Date: August 2010
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

All patients willing to sign consent, complete questionnaire and/ or laboratory studies.

Criteria

Inclusion Criteria:

  • Diagnosis of Vitiligo Vulgaris
  • Ability to sign consent

Exclusion Criteria:

  • Pregnant
  • Inability to sign consent
  • Inability to complete questionnaire
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01206374

Locations
United States, New York
Department of Dermatology, St. Luke's-Roosevelt Hospital Center
New York, New York, United States, 10025
Department of Dermatology, Beth Israel Medical Center
New York, New York, United States, 10003
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
Beth Israel Medical Center
Investigators
Principal Investigator: Nanette Silverberg, MD StLukesNY
  More Information

Publications:
Responsible Party: St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier: NCT01206374     History of Changes
Other Study ID Numbers: 10-027SLRHC
Study First Received: September 20, 2010
Last Updated: May 13, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by St. Luke's-Roosevelt Hospital Center:
Vitiligo Vulgaris

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases

ClinicalTrials.gov processed this record on July 23, 2014